Can-Fite BioPharma Ltd. , a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver and inflammatory disease, and sexual dysfunction.
Can Fite Biopharma stock last closed at $2.19, down 1.35% from the previous day, and has decreased 80.96% in one year. It has underperformed other stocks in the Biotechnology industry by 0.54 percentage points. Can Fite Biopharma stock is currently +1.86% from its 52-week low of $2.15, and -83.02% from its 52-week high of $12.90.
As of Mar 24, 2023, there are 815.75M shares of CANF outstanding. The market cap of CANF is $5.36M. In the past 24 hours, 6576 CANF shares were traded.
How to Buy Can Fite Biopharma Stock
Wondering how to invest in Can Fite Biopharma stock? Here's how.
Decide where to buy Can Fite Biopharma stock: You need to pick an online brokerage, but don't worry - we've researched dozens of online stock brokerages and apps to help you determine where to buy Can Fite Biopharma stock.
Open your brokerage account: Sign up for 0% fee trading with the highest-rated brokerage we've found.
Deposit money your brokerage account: Pick your payment method and add your info.
Research Can Fite Biopharma stock: The Can Fite Biopharma ticker symbol is CANF. Is Can Fite Biopharma stock a good investment? Should you buy shares of CANF? How do CANF's underlying business fundamentals look? Do top analysts think Can Fite Biopharma is a good buy? Why has CANF's stock price moved recently? (Hint: Our stock market analysis tools can help you decide if CANF is a good stock to buy).
Make your CANF trade: Decide if you will purchase CANF shares at the current market price or use a limit order to buy CANF shares at a given price.
Get the latest news on your investment in CANF: Create a watchlist to important updates regarding your position in Can Fite Biopharma stock.
Step 1: Decide where to buy Can Fite Biopharma stock
You will need an online brokerage account to access the NYSEMKT market and buy CANF shares.
A brokerage account allows you to buy and sell a number of financial instruments, including stocks, bonds, mutual funds, and ETFs.
Our recommended brokerage: eToro
In our opinion, eToro is the best place to buy stocks. eToro gives you:
You can invest in stocks with zero commissions: Invest without commissions.
Buy fractional shares: Even if you can't afford a full share, you can still invest in the stock.
Access to world financial markets: From Technology to Energy, New York to London — you can fill your portfolio with stocks from the globe's leading stock exchanges.
Social investing: eToro offers a community with more than 20 million users worldwide. Talk to, learn from, and copy the crypto trades of top investors.
Security: eToro is a regulated and licensed fintech leader.
Buy other financial assets: Such as ETFs and cryptos.
Get $10 towards your share purchase by signing up for an account with eToro today.
Once you have identified the best place to buy Can Fite Biopharma stock, it's very important to research their stock before you buy, so you truly understand the risk as well as the opportunity.
Can Fite Biopharma stock at a glance
CANF Price
$2.19
1w %
-3.52%
1y %
-80.96%
5y %
-98.98%
P/E
-0.37x
P/B
0.54x
P/S
6.89x
PEG
N/A
Revenue
$864.00k
Earnings
-$12.14M
Fore. Rev. Growth
N/A
Fore. Earn. Growth
N/A
Market Cap
$5.36M
Next Earnings
N/A
Next Dividend
N/A
Can Fite Biopharma Overview
WallStreetZen was created to help everyday investors do more in-depth fundamental analysis in less time.
CANF has cash burn of 12477000. It has sufficient cash and short-term investments to cover this for at least one year.
Total CANF debt is lower than 5 years ago, relative to shareholder equity.
There are more short-term assets than long-term liabilities on the CANF balance sheet.
There are more short-term assets than short-term liabilities on the CANF balance sheet.
Negative Financial Indicators:
CANF profit margin has gone down from -1,395.3% to -1,405.4% in the past year.
CANF has a relatively high debt to equity ratio of 0.49.
CANF has $12.77M in cash and short term investments. This is not sufficient to cover its annual cash burn of $12.48M.
Is it a good time to buy CANF stock, according to Wall Street analysts?
Out of 1 sell side analysts who monitor CANF, the consensus analyst rating on Can Fite Biopharma is a Buy
Please note that analyst ratings are not recommendations, nor are they investment advice.
Most Recent CANF Analyst Upgrades/Downgrades
Vernon Bernardino, a top 18% analyst from HC Wainwright & Co. reiterates CANF with a buy rating and maintains their CANF price target from $34.00 to $34.00, on Mar 13, 2023.
Last year, CANF revenue was $864.00k. During the last 5 year, CANF's revenue has gone up by 36.04% per year. This was slower than the Biotechnology industry average of 48.9%.
No, Can Fite Biopharma doesn't provide an income stream by paying out dividends.
What do other traders have to say about CANF?
One of the major reasons eToro is our favorite brokerage is because of its social trading community.
Click below to find out what other community members have to say.
Step 5: Make your CANF trade
You have two primary options:
Market order: A market order is an order to buy or sell a stock at the best price on the market. Market orders are generally sufficient.
Limit order: A limit order lets you buy or sell a stock at a specific price (or better). If you want to ensure you're buying or selling at a specific dollar amount, use a limit order.
Hit the Open Trade button and eToro will execute your order.
If you want more help with buying stocks on eToro, watch the helpful video below:
How much does it cost to buy one Can Fite Biopharma share?
As of Mar 24, 2023, it costs $2.19 to buy one share of Can Fite Biopharma stock.
Remember, eToro's fractional share buying allows you to buy partial shares of stocks and ETFs. Even if you only have $1, you can buy 0.457 shares of CANF.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.